stockrowMedpace Holdings, Inc.
MEDP Healthcare Diagnostics & Research
Medpace Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.5 billion, up 20.0% from fiscal 2024.
- Revenue
- +8.50%
- EPS
- +24.6%
- Free cash flow
- −16.6%
Quarter to September 2026, against a year earlier
Follow MEDP
Alert me
Medpace Holdings, Inc. (MEDP) EBITDA
Medpace Holdings, Inc.'s EBITDA for fiscal 2025 was $563.1M, up 18.3% from $476.1M in fiscal 2024. Over the twelve months to 30 September 2026 it was $634.5M. Over the past ten years it has ranged from $92.8M (fiscal 2015) to $563.1M (fiscal 2025) — the current reading is the highest in ten years. EBITDA has risen for 8 consecutive fiscal years. Medpace Holdings, Inc. ranks 14th of 49 Diagnostics & Research companies by EBITDA.
EBITDA, annual
Embed this chart
Annual newest first
| Period | EBITDA | Change |
|---|---|---|
| FY2025 | $563.1M | 18.26% |
| FY2024 | $476.1M | 31.11% |
| FY2023 | $363.2M | 20.63% |
| FY2022 | $301.0M | 37.00% |
| FY2021 | $219.7M | 18.22% |
| FY2020 | $185.9M | 23.41% |
| FY2019 | $150.6M | 13.45% |
| FY2018 | $132.8M | 28.62% |
| FY2017 | $103.2M | (8.81%) |
| FY2016 | $113.2M | 22.00% |
Quarterly newest first
| Period | EBITDA | Change |
|---|---|---|
| Sep 2026 | $172.1M | 12.11% |
| Jun 2026 | $153.5M | 3.45% |
| Mar 2026 | $148.4M | (7.48%) |
| Dec 2025 | $160.4M | 7.75% |
| 40 more quarters | Free account |
Against its own ten years
EBITDA against peers
| Company | EBITDA |
|---|---|
| DGX Quest Diagnostics Incorporated compare | $2.3B |
| LH Labcorp Holdings Inc. compare | $2.2B |
| ILMN Illumina, Inc. compare | $1.2B |
| ICLR ICON PLC compare | $1.1B |
| RVTY Revvity Inc. compare | $775.8M |
| QGEN QIAGEN N.V. compare | $651.0M |
| MEDP Medpace Holdings, Inc. | $634.5M |
| CRL Charles River Laboratories International, Inc. compare | $553.0M |
| GH Guardant Health, Inc. compare | −$444.9M |
What EBITDA is
EBITDA shows what a company earns from its operations before interest, taxes and the non-cash charges for depreciation and amortization.
Reported line item
More on MEDP
- Revenue
- Net income
- EPS (diluted)
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement